Lion: Raises the target price of AAC TECH (02018) to HK$54.4, maintains "high conviction to outperform the market" rating.
Amid industry headwinds, the companys full-year guidance remains solid. Credit Lyonnais points out that its liquid cooling and optical businesses have made progress and are expected to make a larger contribution starting next year.
Citi released a research report stating that AAC TECH (02018) had a net profit of 901 million RMB in the first half of the year, up 2.9% year-on-year, while the adjusted net profit grew by 37.4% year-on-year. The company expects double-digit revenue growth for the fiscal year 2026, with a steady improvement in gross margin. AAC TECH has made new progress in its liquid cooling and optics businesses. Amid industry headwinds, the company maintains a solid full-year guidance. Citi noted that progress in its liquid cooling and optics businesses is expected to make a greater contribution starting next year. Citi maintains the valuation multiples target for AAC TECH, considering that earnings forecasts for 2026 to 2028 have been raised by 3% to 13%. Consequently, the target price has been adjusted from HKD 50.4 to HKD 54.4, equivalent to a target price-to-earnings ratio of 18 times for this year and next, and maintains a "highly confident outperform" rating.
Related Articles

Citi: Raises the target price for BEKE-W (02423) to HKD 75.4, reiterates as a top pick.

The main oilfield's peak is hard to hide the ambition for increased production! Exxon Mobil Corporation (XOM.US) diversifies its expansion to alleviate crisis, with Morgan Stanley raising its target to $177.

Goldman Sachs: Raises target price for Pharmaron Beijing (03759) to HK$33.2, maintains "Buy" rating.
Citi: Raises the target price for BEKE-W (02423) to HKD 75.4, reiterates as a top pick.

The main oilfield's peak is hard to hide the ambition for increased production! Exxon Mobil Corporation (XOM.US) diversifies its expansion to alleviate crisis, with Morgan Stanley raising its target to $177.

Goldman Sachs: Raises target price for Pharmaron Beijing (03759) to HK$33.2, maintains "Buy" rating.

RECOMMEND





